Astragaloside IV ameliorates cognitive impairment after traumatic brain injury with involvement of NMDAR-related signaling
- 1The Second Hospital & Clinical Medical School, Lanzhou University
- 2Key Laboratory of Biomonitoring and Bioremediation for Environmental Pollution, School of Life Sciences, Lanzhou University
- 3Academician Workstation of the Second Hospital & Clinical Medical School, Lanzhou University
Abstract
Traumatic brain injury (TBI) can cause persistent cognitive impairment accompanied by neuronal and synaptic damage. Astragaloside IV (AS-IV) has neuroprotective properties, but the signaling processes associated with its effects after TBI remain incompletely understood. Adult male mice underwent controlled cortical impact and received intraperitoneal AS-IV during a 28-day post-injury period, with GM1 included as a positive control. Behavioral assessments, immunofluorescence, Golgi-Cox staining, transmission electron microscopy, and immunoblotting were combined with NMDAR antagonist co-treatment and exploratory docking, molecular dynamics, and cellular thermal shift analyses. AS-IV treatment improved cognitive performance and was associated with preservation of dendritic and synaptic structure, increased NMDAR subunit expression, and changes in ERK1/2, CaMKII, and CREB phosphorylation and synapse-associated proteins. The 40 mg/kg dose showed greater effects than 80 mg/kg for several outcomes. Co-treatment with MK-801 or TCN-201 attenuated multiple AS-IV-associated effects, supporting involvement of NMDAR-related signaling. Computational predictions and NMDAR2A thermal stabilization were consistent with possible receptor engagement but did not establish direct binding, binding affinity, or receptor activation. Collectively, these findings suggest that modulation of NMDAR-related signaling alterations may contribute to the cognitive and synaptic structural and molecular effects associated with AS-IV after TBI. However, the present data do not establish direct NMDAR binding or activation, in vivo target occupancy, or NMDAR as the exclusive or primary molecular target of AS-IV.
Related
- Endoplasmic Reticulum Autophagy Enhancement Alleviates Synaptic Plasticity Dysfunction and Ameliorates Cognitive Impairment in SAE Mice by Relieving STING‐Associated Inhibition of PKM2 Activity
- Blockade of the calpain-1/HSP90/TGF-β1 axis by Astragaloside IV ameliorates bleomycin-induced pulmonary fibrosis
- Hepatoprotective Formula 919 ameliorates hepatic steatosis and metabolic disturbance in NAFLD with involvement of AMPK signaling
- 5-Hydroxytryptamine 6 Receptor Antagonism Ameliorates Depression-Like Behaviors in Temporal Lobe Epilepsy Rats with Potential Involvement of the MEF2C/NF-κB Pathway.
- Ishige foliacea Water Extract (KDC22-01) Attenuates Tau Hyperphosphorylation and Ameliorates Scopolamine-Induced Memory Impairment in Mice
BibTeX
@article{jiang2026astragaloside,
title = {{Astragaloside IV ameliorates cognitive impairment after traumatic brain injury with involvement of NMDAR-related signaling}},
author = {Chenglang Jiang and Weiqi Shen and Xin Liu and Yuhang Hui and Boru Hou},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1925675},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1925675/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Astragaloside IV ameliorates cognitive impairment after traumatic brain injury with involvement of NMDAR-related signaling
AU - Chenglang Jiang
AU - Weiqi Shen
AU - Xin Liu
AU - Yuhang Hui
AU - Boru Hou
PY - 2026
DA - 2026/10/29
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1925675
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1925675/full
AB - Traumatic brain injury (TBI) can cause persistent cognitive impairment accompanied by neuronal and synaptic damage. Astragaloside IV (AS-IV) has neuroprotective properties, but the signaling processes associated with its effects after TBI remain incompletely understood. Adult male mice underwent controlled cortical impact and received intraperitoneal AS-IV during a 28-day post-injury period, with GM1 included as a positive control. Behavioral assessments, immunofluorescence, Golgi-Cox staining, transmission electron microscopy, and immunoblotting were combined with NMDAR antagonist co-treatment and exploratory docking, molecular dynamics, and cellular thermal shift analyses. AS-IV treatment improved cognitive performance and was associated with preservation of dendritic and synaptic structure, increased NMDAR subunit expression, and changes in ERK1/2, CaMKII, and CREB phosphorylation and synapse-associated proteins. The 40 mg/kg dose showed greater effects than 80 mg/kg for several outcomes. Co-treatment with MK-801 or TCN-201 attenuated multiple AS-IV-associated effects, supporting involvement of NMDAR-related signaling. Computational predictions and NMDAR2A thermal stabilization were consistent with possible receptor engagement but did not establish direct binding, binding affinity, or receptor activation. Collectively, these findings suggest that modulation of NMDAR-related signaling alterations may contribute to the cognitive and synaptic structural and molecular effects associated with AS-IV after TBI. However, the present data do not establish direct NMDAR binding or activation, in vivo target occupancy, or NMDAR as the exclusive or primary molecular target of AS-IV.
SN - 1663-9812
ER -